German pharma giant Boehringer Ingelheim’s diabetes drug Empagliflozin (type 2 diabetes) which is sold under the brand name Jardiance, its patent expiring on March 11, can allow Indian Pharma companies to launch affordable generics as per Times of India. Empagliflozin works in the Kidneys to prevent absorption of glucose or blood sugar, and this helps to lower blood sugar levels.
With over 10.1 crore Indians living with diabetes as per ICMR study, this shift can ease financial burdens and improve treatment access. Generic versions will cost Rs. 9 to 14 per tablet, which can significantly reduce prices by up to 90 percent from around Rs. 60 per tablet as per sources. This price reduction follows a similar trend seen with newer treatments like sublingual semaglutide, which offers an alternative delivery method for patients who struggle with traditional medications.
India’s diabetes drug market, which is valued at Rs. 20,000 crore, has grown by 43 percent since 2021. Cheaper alternatives will aid heart and kidney health while reducing hospitalization costs.
Companies that leverage bulk active pharmaceutical ingredients can lower production costs and expand their distribution. The move can benefit both businesses and millions of diabetic patients who can afford treatment. Indian Pharma companies can benefit from this development.
Stocks that might benefit from the lower diabetic drug costs from the off-patent of Jardiance are as follows
Mankind Pharma
The company was founded in 1991 and is one of the leading Indian pharmaceutical company known for affordable and quality healthcare products. It operates in 34 countries, offering a wide range of pharmaceutical and consumer healthcare solutions.
With a market capitalization of Rs. 93,253.06 Crores, the shares of Mankind Pharma Limited were trading at Rs. 2,260.25 per equity share, down 2.38 percent from its previous day’s close price of Rs. 2,315.45.
Torrent Pharmaceuticals
This Torrent Group company, which is one of the leading Indian pharma company that specializes in cardiovascular, CNS, GI, and women’s healthcare. It operates in over 50 countries with a strong presence in Brazil and Germany, offering branded generics and generic products.
With a market capitalization of Rs. 1,04,485.26 Crores, the shares of Torrent Pharmaceuticals Limited were trading at Rs. 3,087.35 per equity share, up 0.50 percent from its previous day’s close price of Rs. 3,072.10.
Alkem Laboratories
This company is into manufacturing and marketing generic and specialty products across multiple therapeutic areas. It operates in over 40 countries, with a strong presence in the US and a portfolio of over 800 brands in India.
With a market capitalization of Rs. 55,402.24 Crores, the shares of Alkem Laboratories Limited were trading at Rs. 4,633.65 per equity share, down 1.91 percent from its previous day’s close price of Rs. 4,723.95.
Dr Reddy’s Laboratories
This is a global pharmaceutical company based in Hyderabad, India. It manufactures and markets a wide range of pharmaceuticals, including generics, biosimilars, and APIs, serving customers worldwide with affordable and innovative medicines.
With a market capitalization of Rs. 93,436.68 Crores, the shares of Dr Reddy’s Laboratories Limited were trading at Rs. 1,119.80 per equity share, down 1.15 percent from its previous day’s close price of Rs. 1,132.80.
Lupin
Lupin specializes in generics, branded generics, APIs, biosimilars, and specialty medicines, serving over 100 markets with a diverse portfolio of over 1,200 products.
With a market capitalization of Rs. 91,929.08 Crores, the shares of Lupin Limited were trading at Rs. 2,013.60 per equity share, down 0.75 percent from its previous day’s close price of Rs. 2,028.90.
Written by Santhosh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
